Ten Ministries Jointly Release 15th Five-Year Plan for Pharmaceutical Industry: Innovative Drug Annual Growth Target Exceeds 20%
nashnova research
China's MIIT and nine other agencies released the pharma industry's 15th Five-Year Plan, targeting 20%+ annual growth in innovative-drug revenue and requiring first-in-class drugs to reach 25% of the global total — a policy anchor shifting from fast-follower to first-mover.
What does this plan actually demand?
The plan is jointly issued by ten central agencies led by the MIIT and the NDRC, covering pharma-industry development through 2030.
Core ambition: elevate biopharma into a national strategic pillar industry, with R&D and commercialization "among the world's front ranks."
This means → This is not a vague encouragement letter. It is a quantified industrial roadmap co-signed by ten ministries — a signal of very high policy priority.
How big, how fast?
Revenue target for above-scale pharma companies: over RMB 3.5 trillion.
Innovative-drug industry revenue must grow at 20%+ annually.
China must produce 5 or more drug products each exceeding $1 billion in global annual sales.
In plain terms = The plan wants both a larger pie and individual blockbusters — $1 billion in annual sales is the global industry's threshold for a "mega-drug."
How hard are the innovation targets?
Listed pharma companies must average 10%+ of revenue on R&D annually.
First-in-class drugs (FIC — the first drug worldwide to target a given mechanism) must reach 25%+ of the global total.
200+ innovative medical devices must reach market; pipeline and approval counts must rank "among the world's leading."
This means → FIC at 25% is the plan's hardest benchmark. It demands not "we can do it too" but "we do it first" — a qualitative leap from follow-on innovation to original discovery.
How are companies and clusters sized?
The number of pharma companies with annual revenue above RMB 10 billion must reach 50.
The number of RMB-100-billion-class pharma industrial parks must reach 20.
This reflects a cluster strategy, not just a single-champion bet — 50 large firms plus 20 mega-parks aim to concentrate supply chains geographically and cut coordination costs.
What does this mean for the market?
These are indicative targets, not binding mandates — the direction is clear, but execution depends on companies and local governments.
The 10% R&D-intensity floor will directly raise listed pharma companies' spending, compressing margins short-term while filtering for firms with genuine pipeline depth over time.
In plain terms = The policy draws a steep growth curve. Companies that keep pace will attract more resources; those that fall behind risk being left out — expect accelerating divergence.
市场有风险，内容仅供研究参考，不构成投资建议。